Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
Protagonist Therapeutics plans a virtual 2026 annual stockholder meeting on June 17, 2026 at 10:00 a.m. Pacific Time. Holders of 64,305,185 common shares as of April 22, 2026 may vote.
Stockholders will elect two Class I directors, approve an advisory say‑on‑pay vote, ratify Ernst & Young LLP as 2026 auditor, and vote on adopting a 2026 Equity Incentive Plan. The new plan would draw on 3,352,115 shares remaining under the 2016 plan as of March 31, 2026, add 650,000 new shares, and later recycle certain forfeited awards, supporting continued equity‑based compensation for employees, executives and directors.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel, Ph.D. reported a bona fide gift of 1,460 shares of Common Stock to family and friends. The transaction carried a reported price of $0.00 per share, reflecting that no sale proceeds were received.
Following this gift transfer, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock. The filing shows no option exercises or open-market purchases or sales in this transaction, only the non-cash gift disposition.
Protagonist Therapeutics Chief Financial Officer Ali Asif reported an open-market sale of 1,750 shares of common stock at $105.47 per share on April 20, 2026. According to the filing, the sale was made to cover tax withholding obligations triggered by the settlement of restricted stock units.
After this transaction, Asif directly holds 59,003 shares of Protagonist Therapeutics common stock, indicating that the sale represents a small portion of his overall reported holdings.
PTGX Form 144 notice reporting a proposed sale of 1,750 shares of Common Stock tied to restricted stock vesting on 04/20/2026. The filing also lists recent dispositions by a holder: 46,203 shares on 01/27/2026 and 24,765 shares on 03/26/2026.
Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.
Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.
On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.
The Vanguard Group amended a Schedule 13G/A to report 0% beneficial ownership of Protagonist Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries now report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PTGX Form 144 shows recent proposed and completed sales of Common Stock. The excerpt lists a planned stock option exercise to sell 24,765 shares for cash on 03/26/2026. It also records two completed sales by Asif Ali: 46,203 shares on 01/27/2026 for $3,841,128.28 and 8,588 shares on 01/20/2026 for $708,327.08. Shares outstanding are listed as 63,808,716 as of 03/26/2026.